CURRENT
ISSUE1601
June 29, 2020
The FDA has approved lemborexant (Dayvigo – Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the... read more...
More from issue 1601
Coming Soon
Drugs Past Their Expiration Date
Drugs for Postmenopausal Osteoporosis
Lemborexant (Dayvigo) for Insomnia
Durysta - A Bimatoprost Implant for Glaucoma
Recommend to Your Library
Previous Issues
June 15, 2020 (1600)
June 1, 2020 (1599)
- In Brief: Respiratory Depression with Gabapentinoids
- Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
- Talicia - A 3-Drug Combination for Helicobacter pylori Infection
- Eptinezumab (Vyepti) for Migraine Prevention
- In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes
May 18, 2020 (1598)
May 4, 2020 (1597)
- In Brief: Neuropsychiatric Events with Montelukast
- Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
- Minocycline Foam (Amzeeq) for Acne
- Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
April 20, 2020 (1596)
